RecruitingPhase 1NCT05298995
GD2-CAR T Cells for Pediatric Brain Tumours
Studying Central nervous system embryonal tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bambino Gesù Hospital and Research Institute
- Intervention
- GD2-CART01 (iC9-GD2-CAR T-cells)(biological)
- Enrollment
- 54 enrolled
- Eligibility
- 30 years · All sexes
- Timeline
- 2023 – 2038
Study locations (1)
- Ospedale Pediatrico Bambino Gesù, Roma, Italy, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05298995 on ClinicalTrials.govOther trials for Central nervous system embryonal tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07539441A Study of Mirdametinib in People With Central Nervous System TumorsMemorial Sloan Kettering Cancer Center
- RECRUITINGNCT07198256AI-assisted Diagnosis of Malignant Brain TumorsSecond Affiliated Hospital, School of Medicine, Zhejiang University
- ACTIVE NOT RECRUITINGPHASE1NCT05413304Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral MicrodialysisNational Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT05588453Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the BrainKari Kendra
- RECRUITINGPHASE1NCT05293197Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric PatientsAssistance Publique - Hôpitaux de Paris
- RECRUITINGNCT05711992Rare Embryonal Tumors of the Central Nervous System: International RegistryImmune Oncology Research Institute
- ACTIVE NOT RECRUITINGPHASE2NCT04074096Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain MetastasisUNICANCER
- RECRUITINGNANCT04181684LITT Followed by Hypofractionated RT for Recurrent GliomasUniversity of Maryland, Baltimore